Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Liabilities

Latest as of March 2026: CN¥3.71 Billion CNY ≈ $542.17 Million USD

Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has total liabilities worth CN¥3.71 Billion CNY (≈ $542.17 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Nanjing King-friend Biochemical Pharmace (603707) asset resilience to evaluate the company's liquid asset resilience ratio.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Douglas Emmett Inc
NYSE:DEI
USA $5.87 Billion
Luenmei Quantum Co Ltd
SHG:600167
China CN¥4.37 Billion
Nurix Therapeutics Inc
NASDAQ:NRIX
USA $150.22 Million
ATS CORP
TO:ATS
Canada CA$2.70 Billion
Scandic Hotels Group AB (publ)
ST:SHOT
Sweden Skr50.29 Billion
Aluar Aluminio Argentino
BA:ALUA
Argentina AR$1.40 Trillion
Ningbo Shuanglin Auto Parts
SHE:300100
China CN¥3.70 Billion
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
China CN¥2.89 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nanjing King-friend Biochemical Pharmace balance sheet assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.53 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)

The table below shows the annual total liabilities of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥3.44 Billion
≈ $503.85 Million
+13.95%
2024-12-31 CN¥3.02 Billion
≈ $442.18 Million
-18.89%
2023-12-31 CN¥3.73 Billion
≈ $545.20 Million
-3.05%
2022-12-31 CN¥3.84 Billion
≈ $562.34 Million
+36.56%
2021-12-31 CN¥2.81 Billion
≈ $411.80 Million
-29.22%
2020-12-31 CN¥3.98 Billion
≈ $581.78 Million
+91.67%
2019-12-31 CN¥2.07 Billion
≈ $303.54 Million
+111.40%
2018-12-31 CN¥981.21 Million
≈ $143.58 Million
+52.72%
2017-12-31 CN¥642.50 Million
≈ $94.02 Million
+208.75%
2016-12-31 CN¥208.09 Million
≈ $30.45 Million
+1.65%
2015-12-31 CN¥204.72 Million
≈ $29.96 Million
-59.72%
2014-12-31 CN¥508.26 Million
≈ $74.37 Million
+265.89%
2013-12-31 CN¥138.91 Million
≈ $20.33 Million
--

About Nanjing King-friend Biochemical Pharmaceutical Co Ltd

SHG:603707 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.93 Billion
CN¥13.18 Billion CNY
Market Cap Rank
#6306 Global
#1267 in China
Share Price
CN¥8.16
Change (1 day)
+0.74%
52-Week Range
CN¥6.84 - CN¥11.76
All Time High
CN¥33.62
About

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more